Key clinical point: Patients with type 2 diabetes (T2D) who initiated dulaglutide and liraglutide showed good treatment persistence and similar improvement in glycemic control along with weight loss at 12 months.
Major finding: At 12 months, a high probability of treatment persistence (0.88; 95% CI 0.86-0.90, and 0.83; 95% CI 0.80-0.85, respectively) and a significant reduction in the mean glycated hemoglobin level ( −1.18% and −1.15%, respectively) were observed in patients initiating dulaglutide and liraglutide, along with body weight reduction in both the dulaglutide ( −3.2 kg) and liraglutide ( −3.4 kg) groups.
Study details: The data come from a prospective observational study, TROPHIES, including 2005 patients with T2D who initiated the first injectable treatment with dulaglutide (n = 1014) or liraglutide (n = 991).
Disclosures: This study was funded by Eli Lilly and Company. The authors declared receiving research support, speaker’s fees, or travel support or serving as a clinical investigator or consultant for various sources, including Eli Lilly. Six authors declared being full-time employees and shareholders of Eli Lilly.
Source: Guerci B et al. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): Patient disposition, clinical characteristics, and treatment persistence at 12 months diabetes Obes Metab. 2022 (Jul 25). Doi: 10.1111/dom.14823